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To the editor
Since the first wave of COVID-19, the management of 
patients with severe COVID-19 in intensive care unit 
(ICU) has changed with the widespread use of dexameth-
asone (DXM) in severe patients [1]. Indeed, RECOVERY 
trial [2] showed a decrease in both mortality at day 28 and 
the number of patients who received renal replacement 
therapy (RRT) with DXM. We have previously reported a 
higher than usual incidence of acute kidney injury (AKI) 
(80%) in severe COVID-19 patients treated in ICU [3]. 
Like lung injury, specific SARS-CoV-2 inflammatory pro-
cess was previously suggested in AKI pathogenesis [4, 5] 
and is susceptible to be improved by DXM. Besides, in 
another report, we recently described a 15% incidence of 
chronic kidney disease (CKD) at 3 months after COVID-
19-induced AKI [6], all of these patients developing acute 
kidney disease (AKD) before CKD. The aim of this report 
was to assess the independent clinical effect of DXM on 
the prevention of severe COVID-19-induced AKI.
We carried out a prospective study in the medical ICU 
of the University Hospital of Bordeaux (France) from 
March 17, 2020, to December 20, 2020. All patients 
admitted for a severe COVID-19 were included. DXM 
was exclusively used during the second wave starting 
in Bordeaux (France) on August 6 at 6  mg per day for 
10 days at ICU admission. Patients who presented AKI at 
ICU admission were excluded from the analysis.
Patients characteristics (Table 1)
From March 17, 2020, 126 patients were admitted in our 
unit, 26/126 patients (21%) were excluded because of 
AKI at ICU admission (5 and 21 patients, in first and sec-
ond waves, respectively). DXM was used in all patients 
in the second wave and in none of the first wave. In the 
100 patients included, median age was 63 ± 11  years, 
59/100 (59%) had hypertension, 10/100 (10%) suffered 
from CKD and 48/100 (48%) required mechanical ven-
tilation (MV) in the first 24  h. In the study population, 
56/100 (56%) patients developed AKI: 39/52 (75%) and 
17/48 (35%) patients (p < 0.001), in the first and second 
waves, respectively. AKD was observed in 24/100 (24%) 
of patients: 14/52 (27%) patients in the first wave and 
10/48 (21%) in the second wave (p = 0.49).
In univariate analysis, the use of DXM (OR = 0.18 [0.07–
0.42]), hypertension (OR = 2.31 [1.03–5.29]), SAPSII 
(OR = 1.04 [1.01–1.07]), MV (OR = 8.92 [3.65–23.66]) 
and intravenous fluid therapy (OR = 1.67 [1.20–2.47]) 
were significantly associated with AKI. In multivariate 
analysis, MV (OR = 5.02 [1.68–15.78]) and DXM use 
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Risk factors for AKI (Table 2)
Risk factors for AKD
In univariate analysis, prior CKD (OR = 13.8 [3.14–
97.44]), chronic respiratory disease (OR = 5.16 [1.54–
19.19]), immunosuppression (OR = 7.67 [1.60–55.75]) 
were significantly associated with AKD. In multivariate 
analysis, only prior CKD (OR = 17.73 [2.91–108.08]) was 
significantly associated with AKD (DXM use, OR = 1.10 
[0.32–3.81]).
Table 1 Comparison of baseline characteristics and outcomes
Chronic respiratory disease includes chronic obstructive bronchopneumonia and asthma. The Kidney Disease: Improving Global Outcomes (KDIGO) definition 
was used to define AKI Stages 1, 2 and 3. Serum creatinine (SCr) and urine output were both taken into account. Continuous variables are reported as mean 
(standard deviation) or median [interquartile range] if the variable did not fit a normal distribution and categorical variables are reported as numbers (percentages). 
Quantitative variables were compared using a t-test, and qualitative variables were compared using Fisher’s exact test
AKD, acute kidney disease; AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; D28, day 28; KDIGO, Kidney Disease Improving Global 










Males, No. (%) 76 (76) 38 (73) 38 (79) 0.49
Age (years), mean (SD) 63 ± 11 61 ± 12 66 ± 10 0.009
BMI, mean (SD) 30 ± 5 31 ± 4 30 ± 5 0.20
CKD, No. (%) 10 (10) 4 (8) 6 (12) 0.51
Hypertension, No. (%) 59 (59) 30 (58) 29 (60) 0.84
Diabetes, No. (%) 33 (33) 15 (29) 18 (37) 0.40
Ischemic cardiopathy, No. (%) 13 (13) 4 (8) 9 (19) 0.14
Chronic respiratory disease, No. (%) 17 (17) 7 (13) 10 (21) 0.43
Immunosuppression, No. (%) 9 (9) 4 (8) 5 (10) 0.73
RASi exposure, No. (%) 35 (35) 18 (35) 17 (36) 1
Time between first symptoms and ICU admission (days), mean (SD) 8 ± 4 8 ± 4 8 ± 3 0.74
Time between first symptoms and hospital admission (days), mean (SD) 7 ± 3 7 ± 3 6 ± 4 0.49
Time between hospital admission and ICU admission (days), mean (SD) 1 ± 2 1 ± 2 2 ± 3 0.31
In the first 24 h of ICU hospitalization (before AKI development)
SAPS II, median [IQR] 40 [30–52] 40 [25–60] 40 [33–46] 0.65
Catecholamine use, No. (%) 9 (9) 8 (15) 1 (2) 0.03
Mechanical ventilation, No. (%) 48 (48) 39 (75) 9 (19)  < 0.001
Worst  PaO2/FiO2 ratio, median [IQR] 146 [98–192] 146 [89–205] 146 [116–181] 0.76
Intravenous fluid therapy (L), median [IQR] 2.36 [1.62–3.15] 2.77 [2.13–3.63] 1.94 [1.42–2.70] 0.0023
Dexamethasone use, No. (%) 48 (48) 0 (0) 48 (100) 1
Main outcomes
ICU mortality, No. (%) 19 (19) 7 (13) 12 (25) 0.20
ICU length (days), median [IQR] 12 [6–25] 13 [7–27] 11 [5–22] 0.26
Hospitalization length (days), median [IQR] 26 [14–39] 27 [17–45] 23 [13–30] 0.04
Mortality at D28, No. (%) 21 (21) 9 (17) 12 (25) 0.46
Renal outcomes
AKI, No. (%) 56 (56) 39 (75) 17 (35)  < 0.001
AKI stage 0.24
KDIGO 1, No. (%) 19 (34) 13 (33) 6 (35)
KDIGO 2, No. (%) 18 (32) 15 (38) 3 (18)
KDIGO 3, No. (%) 19 (34) 11 (28) 8 (47)
Renal replacement therapy, No. (%) 12 (12) 7 (13) 5 (10) 0.76
Time between AKI and ICU admission (days), median [IQR] 4 [2–8] 4 [3–7] 4 [1–9] 0.74
AKD, No. (%) 24 (24) 14 (27) 10 (21) 0.49
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Our study suggests an independent effect of DXM to 
prevent from AKI in severe COVID-19 patients. This 
result needs to be confirmed in larger studies.
High rate of vasopressors and greater intravenous fluid 
therapy reported during the first wave imaged the ear-
lier and more frequent use of MV, without reflecting the 
patients’ severity admitted in our ICU. Indeed, patients 
admitted during the second wave had more comorbidi-
ties and were older, which explains the increased mortal-
ity trend observed in our study.
Lack of effect of DXM on RRT in our study can be 
explained by a lack of power and by the too weak effect of 
corticosteroids on AKI.
Our results could indicate an important impact of 
inflammatory state in the pathogenesis of COVID-19-in-
duced AKI. These results support the hypothesis that 
corticosteroid therapy can reduce “inflammatory” AKI 
incidence (specific of COVID-19 infection) but has no 
impact on "maladaptive repair" lesions secondary to AKI 
that can lead to an AKD.
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Table 2 Univariate and multivariate analysis for AKI development
Univariate and multivariate analysis was proceeded using logistic regression. To choose independent variables included in the multivariate model, we allowed one 
independent variable for every 10 dependent variable’s outcomes analyzed. Independent variables with a p-value < 0.20 in the univariate analysis were taken into 
consideration, and we kept variables which were previously described to be associated with AKI or highly associated (p < 0.05) with AKI in the univariate analysis. 
Absence of collinearity was checked
AKI, acute kidney injury; BMI, body mass index; CKD, chronic kidney disease; ICU, intensive care unit; IQR, interquartile; SAPSII, Simplified Acute Physiology Score; SD, 
standard deviation; RASi, renin–angiotensin system inhibitor
Univariate analysis Multivariate analysis
OR (AKI) CI95% OR (AKI) CI 95%
Baseline characteristics
Males, No. (%) 0.88 [0.34–2.22]
Age (years), mean (SD) 1.006 [0.97–1.04] 1.02 [0.97–1.07]
BMI, mean (SD) 1.05 [0.98–1.14]
CKD, No. (%) 3.50 [0.82–24.05] 4.10 [0.71–33.79]
Hypertension, No. (%) 2.31 [1.03–5.29] 1.93 [0.66–5.78]
Diabetes, No. (%) 0.76 [0.33–1.77]
Ischemic cardiopathy, No. (%) 1.91 [0.58–7.50]
Chronic respiratory disease, No. (%) 1.15 [0.40–3.44]
Immunosuppression, No. (%) 1.64 [0.41–8.14]
RASi exposure, No. (%) 1.54 [0.67–3.64]
Time between first symptoms and ICU admission (days), mean (SD) 0.97 [0.87–1.07]
In the first 24 h of ICU hospitalization (before AKI development)
SAPS II, median [IQR] 1.04 [1.01–1.07]
Catecholamine use, No. (%) 3 [0.68–20.87]
Mechanical ventilation, No. (%) 8.92 [3.65–23.66] 5.02 [1.68–15.78]
Worst  PaO2/FiO2 ratio, median [IQR] 0.99 [0.98–1]
Intravenous fluid therapy (L), median [IQR] 1.67 [1.20–2.47] 1.35 [0.90–2.14]
Dexamethasone use, No. (%) 0.18 [0.07–0.42] 0.31 [0.09–0.99]
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